Online inquiry

IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ2987MR)

This product GTTS-WQ2987MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Colorectal Cancer (CRC) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_002253.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3791
UniProt ID	P35968

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2987MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15250MR	IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	TAK-079
GTTS-WQ13282MR	IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	PF-06252616
GTTS-WQ3426MR	IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	AV-299
GTTS-WQ4111MR	IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	BI-204
GTTS-WQ7964MR	IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	GX-17
GTTS-WQ8176MR	IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	HL161
GTTS-WQ11611MR	IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	MGD-006
GTTS-WQ5098MR	IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	CAM-3001

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST